Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

HeartSciences Inc. - Warrant (NQ:HSCSW)

0.1649 +0.0590 (+55.71%)
Streaming Delayed Price Updated: 3:59 PM EDT, Jul 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,152
Open 0.1650
Bid (Size) 0.1300 (2)
Ask (Size) 0.1649 (30)
Prev. Close 0.1059
Today's Range 0.1642 - 0.1650
52wk Range 0.0300 - 0.2000
Shares Outstanding 10,362,284
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
HeartSciences Provides Business Update and Reports Fiscal 2025 Financial Results
From HeartSciences Inc.
Via GlobeNewswire
HeartSciences Receives FDA Breakthrough Device Designation for MyoVista Insights AI-ECG Algorithm for Detecting Aortic Stenosis
Aortic Stenosis is a Serious and Widespread Condition; The AI-ECG Algorithm Offers a Powerful Diagnostic Solution Designed for Seamless Integration with Hospital EHR Systems 
From HeartSciences Inc.
Via GlobeNewswire

Performance

YTD
+230.5%
+230.5%
1 Month
+125.6%
+125.6%
3 Month
+235.8%
+235.8%
6 Month
+369.8%
+369.8%
1 Year
+177.1%
+177.1%

More News

Read More
Foundational US Patent Granted for ECG Assessment of Heart Function, Further Expands HeartSciences’ Patent Portfolio and IP Value
From HeartSciences Inc.
Via GlobeNewswire
HeartSciences Signs First MyoVista Insights™ Platform Customer, Marking Major Commercial Milestone
From HeartSciences Inc.
Via GlobeNewswire
HeartSciences’ CEO Andrew Simpson to Present at Emerging Growth Conference 82 on Wednesday, May 21, 2025
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Host Investor Webinar and Q&A on Wednesday May 14, 2025 - Featuring CEO Andrew Simpson
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Adds Prominent Key Advisors to its Scientific Advisory Board
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Launch of MyoVista Insights™ Platform and Related Early Adopter Program
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire
Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Regains Compliance with Nasdaq Listing Requirements
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences to Present at the LD Micro Invitational XIV Conference
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
From Heart Test Laboratories, Inc.
Via GlobeNewswire
HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
From Heart Test Laboratories, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is HeartSciences Inc. - Warrant publicly traded?
Yes, HeartSciences Inc. - Warrant is publicly traded.
What exchange does HeartSciences Inc. - Warrant trade on?
HeartSciences Inc. - Warrant trades on the Nasdaq Stock Market
What is the ticker symbol for HeartSciences Inc. - Warrant?
The ticker symbol for HeartSciences Inc. - Warrant is HSCSW on the Nasdaq Stock Market
What is the current price of HeartSciences Inc. - Warrant?
The current price of HeartSciences Inc. - Warrant is 0.1649
When was HeartSciences Inc. - Warrant last traded?
The last trade of HeartSciences Inc. - Warrant was at 07/25/25 03:59 PM ET
What is the market capitalization of HeartSciences Inc. - Warrant?
The market capitalization of HeartSciences Inc. - Warrant is 1.71M
How many shares of HeartSciences Inc. - Warrant are outstanding?
HeartSciences Inc. - Warrant has 2M shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.